查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1524233

蝨子治療市場- 按產品類型（非處方藥[氯菊酯、除蟲菊酯]、處方[伊維菌素、多殺菌素、馬拉硫磷]）、類型（品牌、學名藥）、給藥途徑、狀況、劑型、配銷通路- 全球預測（2024 年 - 2032 年） ）

Lice Treatment Market - By Product Type (OTC [Permethrin, Pyrethrin], Prescription [Ivermectin, Spinosad, Malathion]), Type (Branded, Generic), Route of Administration, Condition, Dosage Form, Distribution Channel - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於醫療費用增加和可支配收入增加，2024年至2032年全球蝨子治療市場複合年成長率將超過6.5%。美國經濟分析局報告稱，截至 2023 年最後一個季度的 12 個月裡，美國經濟可支配收入成長了 4.2% 這一年裡，人均收入從 2022 年底的 57,386 美元增至 2022 年底的 61,084 美元。 2023 年。

隨著醫療保健支出的增加，消費者更願意投資管理蝨子感染的有效解決方案。這種趨勢在醫療保健服務和可支配收入水準有所改善的地區尤其明顯，從而促進了對傳統和創新治療替代方案的需求。

意識的提高和不斷變化的監管環境推動了市場擴張，確保治療方法符合嚴格的標準，同時滿足不同消費者的喜好。這些因素共同促進了全球蝨子治療產業的持續成長。

整個蝨子治療市場根據產品類型、類型、給藥途徑、狀況、劑型、配銷通路和地區進行分類。

處方藥細分市場在 2024 年至 2032 年間將實現令人印象深刻的複合年成長率。此外，醫療保健專業人員擴大開出這些藥物，強調它們在管理嚴重感染或非處方藥已被證明不足的情況下的作用。此外，處方治療被認為更可靠，受到尋求更快、更全面的蝨子感染解決方案的個人的青睞，從而增加了這個專業市場的需求。

到 2032 年，品牌產業將佔據相當大的蝨子治療市場。品牌治療通常在功效和安全性方面享有盛譽，這可以增強消費者的信心。他們在藥局和線上平台上的行銷努力和知名度也有助於提高消費者的意識和偏好。此外，品牌治療經常提供額外的好處。例如方便用戶使用的配方或吸引特定消費者需求的附加功能，進一步推動了它們的受歡迎程度。隨著消費者優先考慮有效管理蝨子侵擾的可靠解決方案和便利選擇，品牌區隔市場不斷擴大。

在預測期內，歐洲蝨子治療市場將呈現強勁的複合年成長率。移民和旅行的增加導致了蝨子感染的傳播，從而引發了對有效治療的更高需求。此外，學校和工作場所嚴格的衛生標準需要快速可靠的解決方案，從而推動市場成長。此外，歐洲國家不斷成長的醫療保健支出使人們能夠更多地獲得各種治療選擇，包括處方藥和非處方藥。這些因素，加上人們對個人衛生和健康意識的不斷增強，推動了歐洲蝨子治療產業的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 蝨子感染盛行率上升
      • 輕鬆獲得蝨子治療產品
      • 偏好天然無毒產品
    • 產業陷阱與挑戰
      • 缺乏意識
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2032 年

  • 主要趨勢
  • 非處方藥產品
    • 氯菊酯
    • 除蟲菊酯
    • 其他非處方藥產品
  • 處方藥
    • 伊維菌素
    • 多殺菌素
    • 馬拉硫磷
    • 其他處方藥

第 6 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 品牌化
  • 通用的

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

  • 主要趨勢
  • 口服
  • 專題

第 8 章：市場估計與預測：按條件分類，2021 - 2032 年

  • 主要趨勢
  • 頭蝨病
  • 體蝨病
  • 陰蝨病

第 9 章：市場估計與預測：按劑型，2021 - 2032

  • 主要趨勢
  • 平板電腦
  • 洗髮精
  • 乳液
  • 奶油
  • 其他劑型

第 10 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 其他分銷管道

第 11 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 12 章：公司簡介

  • Alliance Pharma PLC
  • Azurity Pharmaceuticals, Inc.
  • Fleming Medical Ltd.
  • Oystershell Consumer Health
  • Parapro Pharmaceuticals
  • Perrigo Company plc
  • Prestige Consumer Healthcare Inc.
  • Reckitt Benckiser Group plc
  • Sanofi S.A.
  • Thornton & Ross Ltd.
簡介目錄
Product Code: 9176

Global Lice Treatment Market will record over 6.5% CAGR from 2024 to 2032, ushered by increased healthcare expenses and rising disposable incomes. The Bureau of Economic Analysis reported a 4.2% growth in disposable income in the U.S. economy for the 12 months ending in the last quarter of 2023. Over the year, per capital income rose from 57,386 at the end of 2022 to 61,084 at the end of 2023.

As healthcare spending amplifies, consumers are more willing to invest in effective solutions for managing lice infestations. This trend is particularly pronounced in regions where access to healthcare services and disposable income levels have improved, fostering demand for traditional as well as innovative treatment alternatives.

Heightened awareness and evolving regulatory landscapes propel the market expansion, ensuring that treatments meet strict standards while catering to diverse consumer preferences. These factors collectively contribute to the sustained growth of the lice treatment industry globally.

The overall lice treatment market is classified based on product type, type, route of administration, condition, dosage form, distribution channel, and region.

The prescription medications segment will register an impressive CAGR between 2024 and 2032. Prescription medications often offer stronger formulations that can effectively eradicate resistant lice strains, addressing growing concerns over treatment efficacy. Additionally, healthcare professionals increasingly prescribe these medications, emphasizing their role in managing severe infestations or cases where over-the-counter remedies have proven inadequate. Moreover, prescription treatments are perceived as more reliable and are preferred by individuals seeking quicker and more comprehensive solutions to lice infestations, boosting demand within this specialized segment of the market.

By 2032, the branded sector will hold a substantial lice treatment market share. Branded treatments often carry established reputations for efficacy and safety, which instill consumer confidence. Their marketing efforts and visibility in pharmacies and online platforms also contribute to increased consumer awareness and preference. Furthermore, branded treatments frequently offer additional benefits. such as user-friendly formulations or added features that appeal to specific consumer needs, further driving their popularity. The branded segment continues to expand as consumers prioritize trusted solutions and convenient options for managing lice infestations effectively.

During the forecast period, the Europe lice treatment market will showcase a robust CAGR. Increased migration and travel contribute to the spread of lice infestations, prompting higher demand for effective treatments. Moreover, stringent hygiene standards in schools and workplaces necessitate quick and reliable solutions, catapulting the market growth. Additionally, rising healthcare expenditures across European countries enable greater access to a variety of treatment options, including both prescription and over-the-counter remedies. These factors, coupled with a growing awareness of personal hygiene and health, propel the expansion of the lice treatment industry in Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of lice infestations
      • 3.2.1.2 Easy availability of lice treatment products
      • 3.2.1.3 Preference for natural and non-toxic products
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of awareness
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 OTC products
    • 5.2.1 Permethrin
    • 5.2.2 Pyrethrin
    • 5.2.3 Other OTC products
  • 5.3 Prescription medications
    • 5.3.1 Ivermectin
    • 5.3.2 Spinosad
    • 5.3.3 Malathion
    • 5.3.4 Other prescription medications

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Branded
  • 6.3 Generic

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Topical

Chapter 8 Market Estimates and Forecast, By Condition, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Pediculosis capitis
  • 8.3 Pediculosis corporis
  • 8.4 Pediculosis pubis

Chapter 9 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Million)

  • 9.1 Key trends
  • 9.2 Tablets
  • 9.3 Shampoos
  • 9.4 Lotions
  • 9.5 Cream
  • 9.6 Other dosage forms

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

  • 10.1 Key trends
  • 10.2 Hospital pharmacies
  • 10.3 Retail pharmacies
  • 10.4 Other distribution channels

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 Rest of Asia Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest of Latin America
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

  • 12.1 Alliance Pharma PLC
  • 12.2 Azurity Pharmaceuticals, Inc.
  • 12.3 Fleming Medical Ltd.
  • 12.4 Oystershell Consumer Health
  • 12.5 Parapro Pharmaceuticals
  • 12.6 Perrigo Company plc
  • 12.7 Prestige Consumer Healthcare Inc.
  • 12.8 Reckitt Benckiser Group plc
  • 12.9 Sanofi S.A.
  • 12.10 Thornton & Ross Ltd.